- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Anxiety attacks.
Displaying page 1 of 2.
EudraCT Number: 2006-001085-17 | Sponsor Protocol Number: P1V-S01-03-06 | Start Date*: 2007-08-22 | |||||||||||
Sponsor Name:University of Bristol | |||||||||||||
Full Title: Further development of a new model of GAD: The effect of a clinically effective and non−effective dose of lorazepam on CO2 induced anxiety | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003604-14 | Sponsor Protocol Number: RBHP-2020-MOISSET | Start Date*: 2021-03-11 |
Sponsor Name:CHU de Clermont-Ferrand | ||
Full Title: Evaluation of the efficacy of a single infusion of ketamine combined with magnesium sulfate to treat refractory chronic cluster headache | ||
Medical condition: Refractory chronic cluster headache | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003191-39 | Sponsor Protocol Number: | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial | |||||||||||||
Medical condition: DSM-IV Panic disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005055-18 | Sponsor Protocol Number: D1448C00012 | Start Date*: 2006-05-18 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monothe... | ||
Medical condition: Maintenance treatment of patients with Generalised Anxiety Disorder. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) FI (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005708-17 | Sponsor Protocol Number: ELB139202-05 | Start Date*: 2006-03-27 | |||||||||||
Sponsor Name:elbion AG | |||||||||||||
Full Title: International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d... | |||||||||||||
Medical condition: Male and female patients with diagnosis of concurrent panic disorder according to DSM-IV, with or without agoraphobia (DSM IV 300.21 and 300.1) according to Mini International Neuropsychiatric Inte... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003542-68 | Sponsor Protocol Number: | Start Date*: 2016-01-27 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial | |||||||||||||
Medical condition: DSM panic disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004094-17 | Sponsor Protocol Number: 40-41200-98-9269 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Universiteit Utrecht | |||||||||||||
Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. | |||||||||||||
Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000051-34 | Sponsor Protocol Number: DS/06/PDBX/01 | Start Date*: 2007-09-10 | |||||||||||
Sponsor Name:ITALFARMACO | |||||||||||||
Full Title: Randomized, open-label, controlled and multicenter trial on a new pattern of Paroxetine up-titration for Panic Disorder. Comparison between two different dose regimens. | |||||||||||||
Medical condition: Panic Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007336-17 | Sponsor Protocol Number: Version1.10 | Start Date*: 2009-08-06 |
Sponsor Name:Medizinische Universität Wien, Uni. Klinik für Neurologie | ||
Full Title: Blockade of the greater occipital nerve in frequent migraine and medication-overuse headache - a double-blinded, randomized, controlled trial | ||
Medical condition: frequent migraine (defined at least 8 attacks per month) and medication-overuse headache | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2018-000503-16 | Sponsor Protocol Number: P170903J | Start Date*: 2021-02-12 |
Sponsor Name:Assistance Publique- Hôpiaux de Paris | ||
Full Title: Randomized, double-blind, single-centre, randomized study evaluating the efficacy of CLORazepate dipotassium in the treatment of migraine crisis in the emergency department. | ||
Medical condition: Adults of full age, excluding pregnant or breastfeeding women, admitted to the CUC for headaches | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005481-30 | Sponsor Protocol Number: ADX10059-206 | Start Date*: 2009-03-03 | |||||||||||
Sponsor Name:Addex Pharma SA | |||||||||||||
Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modu... | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Ongoing) GB (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004819-12 | Sponsor Protocol Number: FullResponders | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial. | |||||||||||||
Medical condition: Relapsing-Remitting multiple sclerosis (RR-MS), | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004875-11 | Sponsor Protocol Number: CAMG334AIT03 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:NOVARTIS FARMA S.P.A. | |||||||||||||
Full Title: A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN) | |||||||||||||
Medical condition: Episodic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000599-40 | Sponsor Protocol Number: KH176-202 | Start Date*: 2019-10-23 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirme... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000014-38 | Sponsor Protocol Number: THX-G18-001 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Therapix Biosciences Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”) | |||||||||||||
Medical condition: Tourette Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003718-28 | Sponsor Protocol Number: M16-178 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Controlled, Multicenter, Open Label Study with Blinded Assessment of the Efficacy of the Humanized Anti-IL-23p19 Risankizumab Compared to FUMADERM® in Subjects with Moderate to Severe... | |||||||||||||
Medical condition: Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000564-42 | Sponsor Protocol Number: CANNA-TICS | Start Date*: 2017-06-14 | ||||||||||||||||
Sponsor Name:Hannover Medical School | ||||||||||||||||||
Full Title: A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS) | ||||||||||||||||||
Medical condition: Chronic tic disorders and Tourette syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004865-26 | Sponsor Protocol Number: M12-927 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkins... | |||||||||||||
Medical condition: Non-motor symptoms in advanced Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002699-42 | Sponsor Protocol Number: DANBLOCK | Start Date*: 2018-09-28 | |||||||||||
Sponsor Name:Bispebjerg Frederiksberg Hospital | |||||||||||||
Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) | |||||||||||||
Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000434-21 | Sponsor Protocol Number: PRT-PEG-15-10880 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Biogen Portugal | |||||||||||||
Full Title: PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
